Daily Market Updates: Eli Lilly raises 2026 revenue outlook as Zepbound, Mounjaro sales surge

Earnings

Home›Earnings›Results›Eli Lilly raises 2026 revenue outlook as Zepbound, Mou…

Eli Lilly raises 2026 revenue outlook as Zepbound, Mounjaro sales surge

The company now expects 2026 revenue of $85.0 billion to $87.0 billion, above its prior range of $82.0 billion to $85.0 billion.

Reported · Written up by our desk · Results

Eli Lilly topped quarterly expectations and lifted its outlook as sales of its diabetes and weight-loss drugs Zepbound and Mounjaro continue to gain momentum, according to CNBC Markets.

The company now expects 2026 revenue to come in between $85.0 billion and $87.0 billion, up from its prior guidance range of $82.0 billion to $85.0 billion, CNBC Earnings reported.

CNBC World also cited the same raised 2026 revenue forecast as the key update following the quarter.

← Newer storyHong Kong college apologises after admission email sent to 11,139 app…Older story →Ethereum staking reward cut proposal could turn DeFi loops unprofitab…

More like this

EarningsEli Lilly revenue jumps 48% as demand for GLP-1 drugs rises

EarningsDisney beats earnings estimates as parks and streaming gain traction

EarningsCaterpillar posts record quarter and raises guidance on datacenter demand

EarningsDisney stock jumps after surprisingly strong earnings

EarningsNavin Fluorine profit more than doubles in June quarter

Sources

CNBC MarketsEli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

CNBC WorldEli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

CNBC EarningsEli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Earnings

Eli Lilly raises 2026 revenue outlook as Zepbound, Mounjaro sales surge

More like this

Sources

Get the close, explained.